Iovance Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IOVA research report →
About the company
Iovance Biotherapeutics, Inc. , a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells.
- CEO
- Frederick G. Vogt
- IPO
- 2010
- Employees
- 975
- HQ
- San Carlos, CA, US
Price Chart
Get TickerSpark's AI analysis on IOVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.79B
- P/E
- -5.46
- P/S
- 6.28
- P/B
- 2.91
- EV/EBITDA
- -5.12
- Div Yield
- 0.00%
- Gross Margin
- 114.51%
- Op Margin
- -127.16%
- Net Margin
- -123.90%
- ROE
- -50.17%
- ROIC
- -45.27%
- Revenue
- $263.50M · 60.60%
- Net Income
- $-390,978,000 · -5.05%
- EPS
- $-1.09 · 14.84%
- Op Income
- $-403,356,000
- FCF YoY
- 7.64%
- 52W High
- $5.63
- 52W Low
- $1.76
- 50D MA
- $4.03
- 200D MA
- $3.16
- Beta
- 0.69
- Avg Volume
- 15.27M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | WEISER MICHAEL | other | 90,316 |
| Jun 16, 26 | Dukes Iain D. | other | 180,632 |
| Jun 16, 26 | Countouriotis Athena | other | 90,316 |
| Jun 16, 26 | Maynard Ryan D | other | 90,316 |
| Jun 16, 26 | Puri Raj K. | other | 15,000 |
| Jun 5, 26 | Vogt Frederick G | other | 15,625 |
| Jun 5, 26 | Vogt Frederick G | other | 6,638 |
| Jun 5, 26 | Vogt Frederick G | other | 15,625 |
| Jun 5, 26 | GRAF FINCKENSTEIN FRIEDRICH | other | 7,813 |
| Jun 5, 26 | GRAF FINCKENSTEIN FRIEDRICH | other | 3,976 |
Our IOVA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on IOVA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com · Jul 17
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
seekingalpha.com · Jul 16
This Stock Is Up 74% This Year: Is It Too Late to Buy?
fool.com · Jul 8
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
fool.com · Jul 4
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
fool.com · Jun 23
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com · Jun 19
Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds
seekingalpha.com · Jun 17
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
globenewswire.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Community Sentiment
Be the first to call it — is IOVA a buy or a sell from here?